Infectious Diseases News and Research

RSS

New study: Immune molecules can regulate synaptic connections in brain

The number of connections between nerve cells in the brain can be regulated by an immune system molecule, according to a new study from UC Davis. The research, published Feb. 27 in the journal Nature Neuroscience, reveals a potential link between immunity, infectious disease and conditions such as schizophrenia or autism.

27 Feb 2011

Vaccine lawsuit rejected by Supreme Court

The U.S. Supreme Court ruled on Tuesday against the parents of Hannah Bruesewitz, 18, who suffered seizures and permanent brain damage after receiving a diptheria-tetanus-pertussis (DTP) vaccine in 1993. The Bruesewitz family had sued Wyeth who was then the parent company of the maker of the DTP vaccine that Hannah received as an infant.

27 Feb 2011

NIH-funded study finds way to reduce transmission of malaria to humans

Spraying malaria-transmitting mosquitoes with a genetically modified fungus can kill the malaria parasite without harming the mosquito, potentially reducing malaria transmission to humans, according to a new study published in the journal Science. Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the study was led by Raymond J. St. Leger, Ph.D., of the University of Maryland, College Park.

25 Feb 2011

Symposium examines Bruesewitz vs. Wyeth Supreme Court case

A March 29 symposium at the New York Academy of Sciences, "Vaccines Under the Gun: Politics, Science, Media and the Law," will feature a presentation by Daniel J. Thomasch, JD, national lead trial counsel for Wyeth, who was involved in the case decided by the Supreme Court yesterday in which the justices rejected a lawsuit claiming injury from a Wyeth vaccine.

25 Feb 2011

Researchers explain genetic differences that distinguish early-transmitting HIVs-viruses

A new finding from scientists at the National Institutes of Health could help efforts to design vaccines and other prevention tools to block HIV in the early stages of sexual transmission, before infection takes hold. Researchers at the NIH National Institute of Allergy and Infectious Diseases have helped explain genetic differences that can distinguish some early-transmitting HIVs-viruses found in an infected individual within the first month after infection-from forms of HIV isolated later in infection.

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

'Day on Deadly Killers'

Experts from Europe, the US and Asia will present their research results and discuss how new therapeutical approaches against infectious diseases may look like.

22 Feb 2011

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

22 Feb 2011

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

MedTrust Online and Avantra Biosciences announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx multiplex immunoassay system.

22 Feb 2011

Experimental vaccine appears to protect against pneumonia

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.

22 Feb 2011

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

Scientists show bacteria in polluted rivers become resistant to range of antibiotics

Many of the substances in our most common medicines are manufactured in India. Some of these factories release huge quantities of drugs to the environment. Swedish scientists now show that bacteria in polluted rivers become resistant to a range of antibiotics. International experts fear that this may contribute to the development of untreatable infectious diseases world-wide.

21 Feb 2011

Canada Scholar presents research on link between cities and water-related diseases at AAAS conference

Despite clean water and improved public services, water-related diseases continues to spread in cities around the world. Vanier Canada Graduate Scholar Kate Mulligan presents her research on the connection between cities, water and health at the THINK CANADA Press Breakfast at the American Association for the Advancement of Science conference Sunday.

21 Feb 2011

New research demonstrates how climate change can increase exposure, risk of human illness

A panel of scientists speaking today at the annual meeting of the American Association for the Advancement of Science unveiled new research and models demonstrating how climate change could increase exposure and risk of human illness originating from ocean, coastal and Great Lakes ecosystems, with some studies projecting impacts to be felt within 30 years.

20 Feb 2011

New tuberculosis vaccine provides better protection

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.

19 Feb 2011

U.S. scientists assess progress of dengue vaccine at 3-day summit in Puerto Rico

During a meeting in Puerto Rico on Thursday to discuss recent progress towards fighting dengue, researchers voiced optimism over advances in the development of vaccines to prevent the spread of the virus, "which kills 25,000 people every year," Agence France-Presse reports. The three-day summit was hosted by the NIH, CDC and PAHO, according to the news service.

19 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Infectious Diseases News and Research

New study: Immune molecules can regulate synaptic connections in brain

Vaccine lawsuit rejected by Supreme Court

NIH-funded study finds way to reduce transmission of malaria to humans

Symposium examines Bruesewitz vs. Wyeth Supreme Court case

Researchers explain genetic differences that distinguish early-transmitting HIVs-viruses

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

Steroid administration may impact immune system in children with asthma

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

New nanoparticle can help develop vaccines against HIV, malaria

'Day on Deadly Killers'

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

Experimental vaccine appears to protect against pneumonia

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Scientists show bacteria in polluted rivers become resistant to range of antibiotics

Canada Scholar presents research on link between cities and water-related diseases at AAAS conference

New research demonstrates how climate change can increase exposure, risk of human illness

New tuberculosis vaccine provides better protection

U.S. scientists assess progress of dengue vaccine at 3-day summit in Puerto Rico

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

NGS for Infectious Disease Surveillance eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News